Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
.jpg?crop=yes&w=2000&h=1052&a=0,141&itok=MEeRnulM "Doctor examining study participant"){kind=icon}
Phase 3 in primary immune thrombocytopenia
ICON was approached by a drug development sponsor to conduct a global, phase 3 trial in an adult patients with primary immune thrombocytopenia. The trial was part of a four-program study with challenging recruitment timelines.
Fully decentralised clinical trial in heart failure
ICON was approached by a large pharmaceutical company to conduct a fully decentralised placebo-controlled trial, focused
on demonstrating that the drug reduced symptom burden in patients with heart failure.
on demonstrating that the drug reduced symptom burden in patients with heart failure.
Volunteer recruitment for an early phase hot flash study
ICON assisted in the recruitment of participants for a hot flash study that had a set of complex eligibility requirements.
Overcoming challenges and exceeding recruitment timeline
ICON was awarded a study in an adult patient population with Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare indication. Despite complex study logistics ICON’s proactive site and patient support strategy enabled recruitment to be completed ahead of schedule.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
Accelerating clinical trial programs in dermatology
The client tasked ICON plc with managing six phase 3 clinical trials, with overlapping timelines, to further evaluate this
drug in patients with AD.
drug in patients with AD.
Achondroplasia
The client was conducting a a pharmaco-epidemiologic study to characterise the impacts and burden of Achondroplasia across the lifespan.
Overcoming recruitment challenges
ICON successfully overcame site activation and patient recruitment challenges in an early Parkinson’s disease (PD) study.
Agile operations drive enrollment in COVID-19 treatment studies
A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.
genetic seizure disorder in children.
Patient recruitment & retention services
A large biopharmaceutical company with a Phase III trial enrolling 430 advanced Gastric Cancer patients contracted ICON to
support patient enrollment.
support patient enrollment.
In-Home Services: Patient centric practices
Accellacare was contracted by a large pharma organisation to recruit and provide In-Home Services to paediatric patients with autism.
Agile operations drive enrollment in COVID-19 treatment studies
ICON’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.